Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Issue 3 (29th June 2020)

• Record Type: Journal Article
• Authors: Younossi, Zobair M.; Corey, Kathleen E.; Alkhouri, Naim; Noureddin, Mazen; Jacobson, Ira; Lam, Brian; Clement, Stephen; Basu, Rita; Gordon, Stuart C.; Ravendhra, Natarajan; Puri, Puneet; Rinella, Mary; Scudera, Peter; Singal, Ashwani K.; Henry, Linda
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 52:Issue 3(2020)
• Page Start: 513
• Page End: 526
• Publication Date: 2020-06-29
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.15830
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Primary care practitioners (PCPs) and diabetologists are at the frontline of potentially encountering patients with NASH. Identification of those at high risk for adverse outcomes is important. Aim: To provide practical guidance to providers on how to identify these patients and link them to specialty care. Methods: US members of the Global Council on NASH evaluated the evidence about NASH and non‐invasive tests and developed a simple algorithm to identify high‐risk NASH patients for diabetologists and primary care providers. These tools can assist frontline providers in decision‐making and referral to gastroenterology/hepatology practices for additional assessments. Results: The presence of NASH‐related advanced fibrosis is an independent predictor of adverse outcomes. These patients with NASH are considered high risk and referral to specialists is warranted. Given that staging of fibrosis requires a liver biopsy, non‐invasive tests for fibrosis would be preferred. Consensus recommendation from the group is to risk‐stratify patients based on metabolic risk factors using the FIB‐4 as the initial non‐invasive test due to its simplicity and ease of use. A FIB‐4 score ≥1.3 can be used for further assessment and linkage to specialty care where additional technology to assess liver stiffness or serum fibrosis test will be available. Conclusion: Due to the growing burden of NAFLD and NASH, PCPs and diabetologists are faced with increased patient encounters in their clinical practices necessitating referral decisions. To assist in identifying high‐risk NASH patients requiring specialty care, we provide a simple and easy to use algorithm.